Protagonist Therapeutics/$PTGX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Ticker
$PTGX
Sector
Primary listing
Employees
130
Headquarters
Website
PTGX Metrics
BasicAdvanced
$5B
110.44
$0.72
2.20
-
Price and volume
Market cap
$5B
Beta
2.2
52-week high
$93.25
52-week low
$33.31
Average daily volume
1.4M
Financial strength
Current ratio
13.048
Quick ratio
12.938
Long term debt to equity
1.32
Total debt to equity
1.665
Profitability
EBITDA (TTM)
20.03
Gross margin (TTM)
100.00%
Net profit margin (TTM)
21.94%
Operating margin (TTM)
9.09%
Effective tax rate (TTM)
4.50%
Revenue per employee (TTM)
$1,610,000
Management effectiveness
Return on assets (TTM)
1.82%
Return on equity (TTM)
7.80%
Valuation
Price to earnings (TTM)
110.439
Price to revenue (TTM)
24.007
Price to book
7.7
Price to tangible book (TTM)
7.7
Price to free cash flow (TTM)
78.835
Free cash flow yield (TTM)
1.27%
Free cash flow per share (TTM)
1.009
Growth
Revenue change (TTM)
-35.39%
Earnings per share change (TTM)
-73.17%
3-year revenue growth (CAGR)
81.15%
3-year earnings per share growth (CAGR)
-35.37%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Bulls say / Bears say
Detailed Phase 3 VERIFY results showed rusfertide met its primary and all key secondary endpoints in a late-breaking oral presentation at the 2025 ASCO Annual Meeting, underscoring its strong clinical profile in polycythemia vera (Takeda Oncology)
On August 25 2025, rusfertide received FDA Breakthrough Therapy Designation based on 32-week VERIFY data, potentially expediting its regulatory review and NDA submission timeline (FinanzWire)
As of June 30 2025, Protagonist held $673 million in cash, cash equivalents, and marketable securities, providing funding runway through at least the end of 2028 and reducing near-term financing risk (GuruFocus)
Q2 2025 license and collaboration revenue of $5.5 million missed consensus estimates of $7.49 million, reflecting volatile income streams and ongoing execution challenges (GuruFocus)
For the six months ended June 30 2025, license and collaboration revenue plunged to $33.9 million from $259.1 million in H1 2024, underscoring the company’s heavy reliance on one-time milestone payments and lack of recurring revenue (WebDisclosure)
Net loss widened to $34.8 million in Q2 2025 from $30.6 million in Q2 2024, driven by escalating R&D expenses and highlighting persistent profitability pressure ahead of potential product approvals (WebDisclosure)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
PTGX News
AllArticlesVideos
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Accesswire3 days ago
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
Accesswire6 days ago
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Benzinga4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $5B as of November 09, 2025.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 110.44 as of November 09, 2025.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.